.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Cantor Fitzgerald
Healthtrust
Boehringer Ingelheim
Chubb
Fuji
Merck
Deloitte
Citi
Cerilliant

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,419,307

« Back to Dashboard

Which drugs does patent 8,419,307 protect, and when does it expire?


Patent 8,419,307 protects AXIRON and is included in one NDA. There has been one Paragraph IV challenge on Axiron.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 8,419,307

Title:Spreading implement
Abstract: Described are methods comprising applying a liquid pharmaceutical testosterone composition with an implement comprising a support and a receptacle mounted on the support and defining a reservoir space with an open top to receive the liquid, wherein the receptacle includes a flexible membrane integrally forming a base and a wall, the wall being substantially transverse to the base and having a working surface to spread the liquid over the treatment surface, wherein the base has a continuous surface such that liquid cannot pass through the base, wherein the wall includes an inner portion which extends from the base to an upper end and an outer skirt portion, wherein the inner portion and skirt portion form a double-wall structure, and wherein at least the wall is resiliently deformable so the working surface maintains contact with the treatment surface when spreading the liquid.
Inventor(s): Bayly; Peter (Victoria, AU), Bayly; Mark Simon (Victoria, AU), Ahlstrom; Magnus (Victoria, AU), Watkinson; Adam Charles (Victoria, AU)
Assignee: Acrux DDS Pty Ltd. (West Melbourne, Victoria, AU)
Application Number:13/464,556
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Eli Lilly And CoAXIRONtestosteroneSOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo► Subscribe► Subscribe► SubscribeA METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,419,307

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,177,449Spreading implement► Subscribe
9,289,586Spreading implement► Subscribe
8,807,861Spreading implement► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,419,307

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2674661► Subscribe
China101636194► Subscribe
Eurasian Patent Organization200900987► Subscribe
Eurasian Patent Organization015473► Subscribe
European Patent Office2106272► Subscribe
Hong Kong1136228► Subscribe
India2397KON2009► Subscribe
Japan2010515490► Subscribe
Japan5114496► Subscribe
South Korea20090110324► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
QuintilesIMS
Teva
McKesson
Chubb
Farmers Insurance
Federal Trade Commission
Mallinckrodt
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot